Estrogenic Activity Including Bone Enhancement and Effect on Lipid Profile of Luteolin‐7‐O‐glucoside Isolated from Trifolium alexandrinum L. in Ovariectomized Rats |
| |
| Authors: | N. M. Ammar S. S. El‐Hawary D. A. Mohamed A. M. El‐Halawany A. A. El‐Anssary L. T. Abou El‐Kassem R. A. Hussein G. A. Abdel Jaleel A. H. El‐Dosoky |
| |
| Affiliation: | 1. Department of Pharmacognosy, National Research Centre, Giza, Egypt;2. Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt;3. Department of Food Sciences and Nutrition, National Research Centre, Giza, Egypt;4. Faculty of Pharmacy, King Abdul Aziz University, Jedda, Kingdom of Saudi Arabia;5. Department of Pharmacology, National Research Centre, Giza, Egypt |
| |
| Abstract: | Luteolin‐7‐O‐glycoside (LG), an abundant component in many edible plants, was found to be one of the major constituents of the aqueous methanol extract of Trifolium alexandrinum L. family Fabaceae, a fodder plant widely cultivated in Egypt. The estrogenic activity of LG concerning the effect on uterotrophy, lipid profile, weight gain and bone enhancement activity was determined in ovariectomized rat model at a dose of 5 mg/kg. Luteolin‐7‐O‐glycoside showed significant estrogenic effect through the preservation of normal uterine weight and plasma estradiol level. It also significantly inhibited the bone turnover markers plasma bone‐specific alkaline phosphatase, plasma osteocalsin, type I procollagen N‐terminal, and C‐telopeptide of type II collagen levels. It induced a significant improvement in plasma lipid profile. The effect of LG was comparable with estradiol with lower effect on uterine weight. Liver and kidney functions revealed a wide safety of LG at this dose level. The present study revealed that LG may be a promising hormone replacement therapy after being examined thoroughly on human. Copyright © 2016 John Wiley & Sons, Ltd. |
| |
| Keywords: | Trifolium alexandrinum luteolin‐7‐O‐glucoside estrogenic activity bone enhancement activity |
|
|
